Data from Neuronetic’s NeuroStar Outcomes Registry Shows Significant Improvements in Remission/Response for Patients That Complete Full Therapy Course
Neuronetics, Inc. (NASDAQ: STIM) has announced the publication of clinical findings from the NeuroStar Outcomes Registry. These findings, featured in the journal Brain Stimulation: Basic, Translational, and Clinical Research in Neuromodulation, establish a link between the number of treatment sessions and improved outcomes for depression patients receiving NeuroStar therapy. The results offer actionable insights for clinicians prescribing transcranial magnetic stimulation (TMS) therapy for individuals with major depressive disorder (MDD).
The study encompassed over 7,000 patients and revealed that patients who completed a full course of 36 TMS sessions experienced an 82% greater improvement in remission rates and a 43% greater improvement in response rates compared to those who concluded their TMS treatment with fewer than 30 sessions. Historically, patients often discontinue TMS therapy prematurely, but these findings indicate that ending treatment before the full 36 sessions can substantially diminish its effectiveness. In addition, the study’s analysis revealed that some individuals with a slower initial response might benefit from extended treatment beyond the standard 36 sessions.
Cory Anderson, Senior Vice President of R&D and Clinical, emphasized the significance of patients adhering to the entire prescribed treatment course. He stated, “These findings underscore the importance of patients completing the full prescribed treatment course to achieve the best outcomes.” Anderson further noted that Neuronetics offers its proprietary TrakStar platform to enhance patient support and adherence. Those utilizing TrakStar features experienced a 20% increase in the number of patients completing the full 36 treatments.
The NeuroStar Outcomes Registry is the world’s largest repository of depression outcomes. Utilizing Neuronetics’ proprietary TrakStar management system, it gathers real-world treatment data using NeuroStar Advanced Therapy, an FDA-cleared and non-invasive treatment for depression and other mental health conditions. NeuroStar is FDA-cleared for adults with major depressive disorder (MDD), as an adjunct for adults with obsessive-compulsive disorder (OCD), and to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression). NeuroStar Advanced Therapy is also the leading transcranial magnetic stimulation (TMS) treatment for MDD in adults with over 156,000 patients treated and 5.6 million treatments delivered to date.